Defunct Company
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,500
NCT00610051
ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 31, 2023
Completion: Dec 31, 2026